# Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

> **NCT05309668** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 36 (actual)

## Conditions studied

- Neurofibromatosis Type 1

## Interventions

- **DRUG:** Selumetinib granule formulation
- **DRUG:** Selumetinib capsule formulation

## Key facts

- **NCT ID:** NCT05309668
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-21
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-04-28
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05309668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05309668, "Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05309668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*